Antitumor effect of a new antibiotic, neothramycin.
A new anthramycin-group antitumor antibiotic, neothramycin, isolated from a Streptomyces culture, showed activity against experimental tumors such as lymphocytic leukemia P388 ascites sarcoma-180, hepatoma AH130, Walker carcinosarcoma-256 and mouse mammary adenocarcinoma (CCMT). In particular, the tumor growth inhibition ratio was as high as 96% when neothramycin was injected intraperitoneally at a daily dose of 2 mg/kg into Wistar strain rats previously inoculated with Walker carcinosarcoma-256 by the subcutaneous route. Successive intraperitoneal injections of the compound were more effective than a single injection with the P388 system.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D007928:Lethal Dose 50; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D001570:Benzodiazepinones; C012453:neothramycins